Table 2.
Comparison of Plasma TC, LDL-C, HDL-C, and TG Statistical Indicators Before and After Intervention Within P-Ea and E-Pb Groups in Two Phases
| Placebo–Vitamin E | Vitamin E–Placebo | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Variables | Mean ± SDc (mg/dL) |
Median (mg/dL) |
Percentile 25 (mg/dL) |
Percentile 75 (mg/dL) |
Wilcoxon Signed Rank P value |
N | Variables | Mean ± SD (mg/dL) |
Median (mg/dL) |
Percentile 25 (mg/dL) |
Percentile 75 (mg/dL) |
P value |
| 35 | TCd before phase I | 201.34 ± 35.21 | 204.00 | 169.00 | 221.00 | 0.152 | 38 | TC before phase I | 204.79 ± 36.41 | 200.00 | 184.00 | 220.00 | 0.530 |
| 35 | TC after phase I | 195.29 ± 38.64 | 195.00 | 162.00 | 219.00 | 38 | TC after phase I | 208.16 ± 36.45 | 203.00 | 178.00 | 231.00 | ||
| 32 | TC before phase II | 197.06 ± 34.90 | 192.00 | 174.00 | 224.00 | 0.080 | 38 | TC before phase II | 206.89 ± 34.04 | 202.50 | 181.00 | 238.00 | 0.530 |
| 32 | TC after phase II | 201.72 ± 33.60 | 190.50 | 174.50 | 221.00 | 38 | TC after phase II | 210.47 ± 44.34 | 207.00 | 175.00 | 233.00 | ||
| 35 | LDL-Ce before phase I | 124.26 ± 28.67 | 124.80 | 104.80 | 151.00 | 0.200 | 38 | LDL-C before phase I | 121.27 ± 34.11 | 116.90 | 100.40 | 143.20 | 0.999 |
| 35 | LDL-C after phase I | 118.91 ± 32.73 | 109.20 | 95.20 | 136.60 | 38 | LDL-C after phase I | 121.26 ± 42.78 | 124.10 | 93.40 | 148.20 | ||
| 32 | LDL-C before phase II | 120.31 ± 28.70 | 117.60 | 104.00 | 134.80 | 0.180 | 38 | LDL-C before phase II | 127.48 ± 29.48 | 124.80 | 107.20 | 153.20 | 0.870 |
| 32 | LDL-C after phase II | 124.27 ± 27.01 | 120.20 | 107.40 | 138.60 | 38 | LDL-C after phase II | 126.64 ± 37.21 | 121.80 | 101.40 | 153.20 | ||
| 35 | HDL-Cf before phase I | 48.41 ± 11.90 | 45.00 | 41.00 | 56.00 | 0.640 | 38 | HDL-C before phase I | 54.29 ± 19.15 | 53.00 | 45.00 | 58.10 | 0.230 |
| 35 | HDL-C after phase I | 49.06 ± 13.05 | 46.00 | 40.00 | 61.00 | 38 | HDL-C after phase I | 52.28 ± 19.33 | 48.00 | 42.00 | 55.00 | ||
| 32 | HDL-C before phase II | 45.82 ± 10.98 | 44.00 | 38.00 | 52.00 | 0.999 | 38 | HDL-C before phase II | 49.97 ± 9.49 | 49.00 | 44.00 | 55.00 | 0.450 |
| 32 | HDL-C after phase II | 45.56 ± 12.02 | 43.50 | 36.50 | 50.50 | 38 | HDL-C after phase II | 49.16 ± 8.58 | 48.00 | 45.00 | 54.00 | ||
| 35 | TGg before phase I | 139.97 ± 64.33 | 124.00 | 99.00 | 172.00 | 0.710 | 38 | TG before phase I | 140.24 ± 54.82 | 126.00 | 103.00 | 175.00 | 0.460 |
| 35 | TG after phase I | 136.57 ± 60.31 | 124.00 | 89.00 | 174.00 | 38 | TG after phase I | 146.74 ± 59.80 | 132.50 | 108.00 | 179.00 | ||
| 32 | TG before phase II | 154.67 ± 73.88 | 133.00 | 97.00 | 185.00 | 0.440 | 38 | TG before phase II | 141.74 ± 53.52 | 138.50 | 94.00 | 195.00 | 0.010 |
| 32 | TG after phase II | 160.97 ± 98.50 | 129.00 | 97.00 | 200.00 | 38 | TG after phase II | 167.47 ± 71.32 | 170.00 | 108.00 | 202.00 | ||
Notes: aPlacebo–vitamin E; bVitamin E–placebo; cStandard derivation; dTotal cholesterol; eLow density lipoprotein; fHigh density lipoprotein; gTriglyceride.